Shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the seventeen ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, twelve have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $302.33.
Several brokerages have issued reports on CRL. Argus set a $330.00 price objective on shares of Charles River Laboratories International in a research report on Thursday, September 17th. Jefferies Financial Group raised their price target on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the company a “buy” rating in a report on Monday, September 28th. UBS Group initiated coverage on shares of Charles River Laboratories International in a research note on Wednesday, September 30th. They set a “buy” rating and a $357.00 price target on the stock. Barclays boosted their price objective on shares of Charles River Laboratories International from $300.00 to $330.00 and gave the stock an “overweight” rating in a report on Friday, September 25th. Finally, Mizuho increased their price target on Charles River Laboratories International from $264.00 to $295.00 and gave the company a “neutral” rating in a report on Friday, September 25th.
View Our Latest Research Report on Charles River Laboratories International
Insider Transactions at Charles River Laboratories International
In other Charles River Laboratories International news, Director Nancy C. Andrews sold 573 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total transaction of $163,442.52. Following the transaction, the director directly owned 1,438 shares in the company, valued at $410,175.12. This represents a 28.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Victoria L. Creamer sold 4,179 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the transaction, the executive vice president directly owned 30,051 shares of the company’s stock, valued at approximately $7,788,017.16. This represents a 12.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 118,169 shares of company stock valued at $35,191,216 over the last ninety days. 1.30% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Charles River Laboratories International
A number of institutional investors have recently modified their holdings of CRL. Dimensional Fund Advisors LP raised its holdings in Charles River Laboratories International by 14.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock worth $285,001,000 after purchasing an additional 210,260 shares during the last quarter. Bank of America Corp DE lifted its stake in Charles River Laboratories International by 5.0% in the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock valued at $195,792,000 after acquiring an additional 54,500 shares during the last quarter. Amundi boosted its stake in shares of Charles River Laboratories International by 175.2% during the 1st quarter. Amundi now owns 773,315 shares of the medical research company’s stock worth $133,397,000 after acquiring an additional 492,301 shares during the period. Van Berkom & Associates Inc. grew its position in shares of Charles River Laboratories International by 11.2% in the first quarter. Van Berkom & Associates Inc. now owns 501,152 shares of the medical research company’s stock valued at $86,449,000 after purchasing an additional 50,462 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Charles River Laboratories International by 2.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 225,314 shares of the medical research company’s stock worth $51,099,000 after buying an additional 6,401 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.
Charles River Laboratories International Price Performance
Charles River Laboratories International stock opened at $359.34 on Friday. Charles River Laboratories International has a 12-month low of $146.20 and a 12-month high of $379.63. The firm’s 50-day moving average is $302.09 and its two-hundred day moving average is $222.34. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The stock has a market capitalization of $17.15 billion, a P/E ratio of -74.09, a P/E/G ratio of 3.36 and a beta of 1.40.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities analysts predict that Charles River Laboratories International will post 11.38 earnings per share for the current year.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.
Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.
Featured Stories
- Five stocks we like better than Charles River Laboratories International
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
